. 2016 Jun 16;16:32. doi: 10.1186/s12905-016-0311-9

Table 1.

Eligibility criteria

Inclusion Criteria	Exclusion Criteria
• Post-menopausal women, >52 weeks of amenorrhea and a serum oestradiol of 0-120pmol/L and an FSH of >20 IU/L • Lateral hip pain reproduction in 3 of 5 pain provocation tests (Trendelenburg test, palpation of the greater trochanter, FABER, resisted external derotation test, modified resisted external derotation test) • Have sufficient English skills to be able to read and understand the information and consent form due to the risks involved with participating in the study.	• Known adverse reaction to any form of hormone therapy • Use of any form of female hormone supplementation within the last 12 weeks • Display high risk factors for deep vein thrombosis (DVT) using the Wells score system [85] and/or pulmonary embolism (PE). • Current smoker • History of stroke, severe menstrual migraine, endometrial sarcoma, breast cancer, severe hyperlipidaemia, chronic liver disease, thyroid disease, lupus, hysterectomy and oophorectomy • HbA1c >8 % • Current cholecystitis, fibroids or undiagnosed abnormal uterine bleeding • Platelet-rich plasma (PRP), analogous blood injection (ABI) or corticosteroid injection into the hip region in the last 12 weeks • History of hip trauma or surgery on the affected side • Any other musculoskeletal, neurological and cardiorespiratory condition/s affecting their ability to participate in the study.

Inclusion Criteria

Exclusion Criteria

• Post-menopausal women, >52 weeks of amenorrhea and a serum oestradiol of 0-120pmol/L and an FSH of >20 IU/L
• Lateral hip pain reproduction in 3 of 5 pain provocation tests (Trendelenburg test, palpation of the greater trochanter, FABER, resisted external derotation test, modified resisted external derotation test)
• Have sufficient English skills to be able to read and understand the information and consent form due to the risks involved with participating in the study.

• Known adverse reaction to any form of hormone therapy
• Use of any form of female hormone supplementation within the last 12 weeks
• Display high risk factors for deep vein thrombosis (DVT) using the Wells score system [85] and/or pulmonary embolism (PE).
• Current smoker
• History of stroke, severe menstrual migraine, endometrial sarcoma, breast cancer, severe hyperlipidaemia, chronic liver disease, thyroid disease, lupus, hysterectomy and oophorectomy
• HbA1c >8 %
• Current cholecystitis, fibroids or undiagnosed abnormal uterine bleeding
• Platelet-rich plasma (PRP), analogous blood injection (ABI) or corticosteroid injection into the hip region in the last 12 weeks
• History of hip trauma or surgery on the affected side
• Any other musculoskeletal, neurological and cardiorespiratory condition/s affecting their ability to participate in the study.